Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 5, 2026Stem Cells InternationalOpen Access

Derivation and Pluripotency Validation of Six iPSC Lines From Amniotic Fluid Carrying Intermediate α‐Thalassemia Genotypes (‐‐ 3.7 /α SEA and ‐‐ 4.2 /α SEA )

View Full Paper
Ask AI
Bookmark
Share

Authors

QCQingyun ChenXJXinxing JiangXXXinhuai Xue

Discussion

Loading...

Member takes

Overview

Randomized trial establishes iPSC lines with pluripotency from TI fetuses, indicating potential for disease study.

Key Points

  • The study aims to derive and validate induced pluripotent stem cells from intermediate α-thalassemia fetuses to explore disease mechanisms.
  • Reprogrammed amniotic fluid cells from six fetuses using nonintegrating episomal vectors via electro-transfection.
  • Characterized iPSCs with assays for pluripotency markers, genetic analysis, and differentiation potential assessments.
  • In vivo teratoma formation and in vitro hematopoietic differentiation validated pluripotency and hematopoietic potential.
  • Six stable iPSC lines were derived from intermediate α-thalassemia fetuses and retained the corresponding genotype.
  • All lines formed teratomas containing tissues from all three germ layers, demonstrating pluripotency.
  • In vitro differentiation successfully generated CD34+/CD43+ hematopoietic progenitors with functional validation through CFU assays.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a22688f763171746d547256https://doi.org/10.1155/sci/9951684
View Full Paper
Ask AI
Bookmark
Share